| Similar Articles |
 |
IEEE Spectrum April 2013 Neil Savage |
Path Found to a Combined MRI and CT Scanner Omni-tomography could add together the advantages of several medical imaging technologies  |
Chemistry World June 21, 2006 Katharine Sanderson |
Peptide Agent Tracks Angiogenesis A molecular imaging agent that can track the progress of tumour growth is about to be trialled by GE Healthcare.  |
The Motley Fool August 31, 2010 Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.  |
The Motley Fool December 3, 2010 Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move.  |
Chemistry World October 16, 2007 Ned Stafford |
Germany's 900m Euro Molecular Imaging Drive Five German companies and the Federal Ministry of Education and Research are to spend almost a billion euros in an effort to strengthen the nation's international competitiveness in molecular imaging, which will require a large dose of nanotechnology research.  |
The Motley Fool November 30, 2010 Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.  |
Managed Care January 2005 Maureen Glabman |
Health Plans Strain To Contain Rapidly Rising Cost of Imaging PET, CT, MRI -- these and other imaging technologies are valuable but costly. Aetna, Cigna, and a few other plans lead in clamping down on unnecessary use.  |
The Motley Fool January 28, 2010 Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.  |
Chemistry World March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations  |
The Motley Fool January 29, 2010 Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.  |
InternetNews July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.  |
The Motley Fool July 12, 2010 Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.  |
The Motley Fool February 28, 2011 Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.  |
The Motley Fool October 11, 2010 Travis Hoium |
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004.  |
Chemistry World July 2010 |
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon  |
The Motley Fool March 30, 2011 Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.  |
The Motley Fool September 2, 2010 Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.  |
The Motley Fool February 16, 2010 Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.  |
BusinessWeek March 4, 2010 Frederik Balfour |
The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care.  |
BusinessWeek July 15, 2010 Lopatto & Matsuyama |
The Race for Diagnostic Tests for Alzheimer's GE, Bayer, and Avid are vying to be first to market an early test for Alzheimer's.  |
Bio-IT World January 12, 2004 Michael A. Greeley |
What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential.  |
Pharmaceutical Executive April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.  |
The Motley Fool September 20, 2010 Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time.  |
The Motley Fool March 4, 2010 Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.  |
The Motley Fool July 30, 2010 Anand Chokkavelu |
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.  |
The Motley Fool May 11, 2010 Ryan McBride |
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals.  |
Chemistry World July 16, 2010 Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.  |
The Motley Fool May 21, 2010 Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.  |
The Motley Fool April 26, 2011 Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.  |
The Motley Fool December 21, 2010 Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.  |
BusinessWeek May 27, 2010 Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.  |
Pharmaceutical Executive December 1, 2010 William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.  |
BusinessWeek August 26, 2010 Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.  |
The Motley Fool April 29, 2011 Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.  |
The Motley Fool October 27, 2010 Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.  |
The Motley Fool June 25, 2010 Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.  |
Chemistry World November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?  |
The Motley Fool December 2, 2010 Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.  |
The Motley Fool July 28, 2010 Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage  |
Managed Care June 2005 |
Quick Results, Not Self-Referrals, Fuel Increase in Imaging Tests The researchers say that if self-referral were an important driver of the number of imaging services, they would have seen an acceleration in the growth of imaging services from 2001 to 2003 to offset the reductions in physician income brought about by reductions in the conversion factor.  |
The Motley Fool January 8, 2010 Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.  |
The Motley Fool September 14, 2010 Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason.  |
BusinessWeek January 21, 2010 John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.  |
The Motley Fool March 3, 2011 Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.  |
The Motley Fool July 30, 2010 Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.  |
The Motley Fool January 25, 2010 Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.  |
Chemistry World June 2011 |
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress  |
The Motley Fool March 31, 2011 Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.  |
The Motley Fool September 15, 2010 Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer.  |
The Motley Fool March 16, 2011 Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.  |